Sign in
RLMD Stock Price, Chart, Stats & News
Relmada Therapeutics, Inc.
Save
Relmada Therapeutics, Inc. (RLMD) does not currently pay a dividend.
394.91M
Market cap
–
Current P/E
–
Forward P/E
RLMD chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -61.05% |
ROE | -170.83% |
D/E | – |
Interest coverage ratio | – |
RLMD valuation
P/E | – |
P/S | – |
P/B | 5.07x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | -0.42x |
EV multiple | -8.04x |
About
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone.
Similar securities
Based on sector and market capitalization
Report issue